Executive Salary
avg.$234,101
Biogen Idec
Life Science/Biotechnology
Cambridge City, IN, United States
Description
Biogen Inc., founded in 1978, is a publicly traded biotechnology company headquartered in Cambridge, Massachusetts. The company specializes in the discovery, development, and delivery of therapies for neurological diseases. It serves both business-to-business (B2B) and business-to-consumer (B2C) markets, with a focus on innovative treatments for conditions such as multiple sclerosis, Alzheimer’s disease, and other neurodegenerative disorders. As of the latest data, Biogen employs approximately 7,600 staff members and reported an annual revenue of $9.84 billion. The company's operations emphasize research and development to advance therapies in the neurological field, maintaining a significant presence in the United States. Its organizational structure primarily consists of its main headquarters, with no publicly available information on subsidiaries or organizational subdivisions.
Experteer Insights
Experteer Briefing
Company Trajectory
Founded in 1978, Biogen Idec is headquartered in Cambridge, Massachusetts, United States, and has developed into a leading biotechnology company specializing in therapies for neurological diseases. Its origins were rooted in pioneering research and a commitment to innovative treatment development. Over the decades, Biogen Idec has marked key milestones, including strategic expansions and rebrandings, as well as notable product launches that have established it as an industry frontrunner. The company maintains a non-start-up profile, continuing to broaden its reach in the global healthcare arena and focusing on long-term growth and innovation.
Financial Setup
Biogen Idec is a publicly traded entity composed of approximately 7,600 employees. The firm serves both business-to-business and business-to-consumer markets, leveraging its strong research and development capabilities to drive sustained financial performance. Over the years, its business model has concentrated on discovering, developing, and delivering advanced therapies for neurological disorders. This model, accompanied by an evolving revenue base and significant market presence, supports the company’s ability to remain competitive and adaptive within the biotechnology sector.
Development & Outlook
The company has an extensive product portfolio, including notable treatments such as Avonex, Plegridy, Tecfidera, and Tysabri for multiple sclerosis, Spinraza for spinal muscular atrophy, and Aduhelm for Alzheimer’s disease. Biogen Idec continues to invest heavily in research and development, producing a robust pipeline and a substantial number of patents related to neurological therapies. Sustainability is a priority, as evidenced by repeated inclusion in the Dow Jones Sustainability World Index. Biogen Idec is also recognized for its commitment to diversity and inclusion, hosting initiatives such as the Women’s Innovation Network and making significant contributions to patient communities. Looking ahead, Biogen aims to reinforce its leadership in neurological innovation and further advance its social and environmental impact.
Vacancies
Head of Translational Immunology
Biogen Idec
Cambridge, MA - USA
Principal Associate Scientist, Translational Pathology
Biogen Idec
Cambridge, MA - USA
Machine Learning Engineer, Operations and Health Systems Research
Biogen Idec
Cambridge, MA - USA
Machine Learning Engineer, Operations and Health Systems Research
Biogen Idec
Research Triangle Park, NC - USA
Associate Director Forecasting-Lupus/MS
Biogen Idec
Cambridge, MA - USA